Recent Updates
Recently added Catalysts
VCRE Positive Sentiment

Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Key Takeaway: Vicore Pharma announced it will attend the DNB Carnegie Nordic Healthcare Conference on November 24, 2026. Chief Operating Officer Mikael Nygård will join a panel discussion on idiopathic pulmonary fibrosis. The company highlighted its lead drug buloxibutid, currently in a Phase 2b trial for this condition.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vicore Pharma will participate in a significant healthcare conference.
  • The company is advancing its lead program in idiopathic pulmonary fibrosis.
  • Mikael Nygård will represent Vicore Pharma at the event.

Full Press Release Details

The first and only All-in-one subscription platform offering all of your PR Distribution and Media Outreach Tools in one single solution. Monthly & Annual Subscriptions.
Find & create journalist lists with the most up to date database in the industry.
Personalize and customize your pitch for maximum engagement.
Discover your brand, industry, and competitor mentions.
Now you can track every mention, every conversation, and every shift in sentiment — all from the platform you're already using.
Turn your PR data into actionable intelligence with comprehensive reporting and analytics on every campaign.
Catch issues before our editors do. ACCESS Verified gives you a real-time first pass on your press release so you can submit with confidence — every time.
The first and only All-in-one subscription platform that offers you the ability to manage all of your IR communications needs from a single source. Explore our IR subscriptions
Explore how you can upgrade your IR Site today.
Ensure your IR Site is accessible for your entire audience.
Experience seamless calls with our dedicated team of domestic operators.
Easily send your releases out with quick turnarounds and no extra fees.
Host your day knowing you've got the most experienced webcast team in the industry.
Provide a secure and confidential reporting channel to protect your organization and employees.
Streamline your PR & IR needs with one platform.
Easily schedule and manage your investor meetings with our comprehensive and easy to use software.
Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Whether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
We simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
We understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
Designed for brands that need help consistently fueling their content strategy and calendar with optimized press releases, blogs, and more…
Tailored for brands with a solid content strategy seeking support for effectively reaching and engaging the media.
Made for brands that need more comprehensive support building and managing their content strategy, media outreach and engagement plan.
Personalized support to optimize your platform, including tailored journalist list creation, pitch guidance, and monitoring setup.
Continual support and management including ongoing list creation, pitch creation and modifications, monitoring adjustments, and additional reporting and analytics review.
Press Release creation and optimization for SEO and audience engagement
Back to the Newsroom Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference Tuesday, 17 November 2026 02:15 AM
STOCKHOLM, SE / ACCESS Newswire / November 17, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the DNB Carnegie Nordic Healthcare Conference.
Format : Panel discussion and 1×1 meetings
Panel: Idiopathic Pulmonary Fibrosis | Three shots at reversing IPF - the Nordic fibrosis race
Date and time: Tuesday, November 24, 2026, 1:45-2:05 PM CET
Participant: Mikael Nygård, Chief Operating Officer
For further information, please contact: Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
Attachments Vicore Pharma to Participate in the DNB Carnegie Nordic Healthcare Conference

Frequently Asked Questions

When will Vicore Pharma participate in the conference?

Vicore Pharma will participate on November 24, 2026.

Who will represent Vicore Pharma at the conference?

Mikael Nygård, the COO, will represent the company.

What is the focus of the panel discussion?

The panel will discuss idiopathic pulmonary fibrosis.

What is Vicore Pharma's lead program?

The lead program is buloxibutid, targeting respiratory diseases.

Last updated: Nov 17, 2026